EGFR-Mutated mNSCLC: Evolving Treatment Strategies and Post-ESMO 2025 Clinical Insights - Episode 3

EGFR-Mutated NSCLC: Refining Patient Selection for Monotherapy vs Combination Therapy

EP. 1: EGFR-Mutated NSCLC: Key Data Highlights from ESMO 2025
EP. 2: EGFR-Mutated NSCLC: Defining the Role of Combination Therapy Post-FLAURA2
Now Viewing
EP. 3: EGFR-Mutated NSCLC: Refining Patient Selection for Monotherapy vs Combination Therapy
EP. 4: EGFR-Mutated NSCLC: Balancing Efficacy, Toxicity, and Patient Factors
EP. 5: EGFR-Mutated NSCLC: Practical Barriers and Strategies for Optimal Care
EP. 6: EGFR-Mutated NSCLC: Measuring What Truly Matters to Patients
EP. 7: EGFR-Mutated NSCLC: Supportive Care Strategies to Enhance Adherence and Quality of Life
EP. 8: EGFR-Mutated NSCLC: Dosing Innovations to Improve Convenience and Reduce Toxicity
EP. 9: EGFR-Mutated NSCLC: Incorporating MET Status Into Treatment Decisions
EP. 10: EGFR-Mutated NSCLC: ctDNA for Resistance and Treatment Planning
EP. 11: EGFR-Mutated NSCLC: Using Post-Progression Data to Guide 1L Strategies
EP. 12: EGFR-Mutated NSCLC: Emerging Therapies Shaping Future Sequencing
EP. 13: EGFR-Mutated NSCLC: Evolving Treatment Algorithms

Related Content:

EGFR-Mutated mNSCLC: Evolving Treatment Strategies and Post-ESMO 2025 Clinical Insights
EGFR-Mutated NSCLC: Evolving Treatment Algorithms
EGFR-Mutated NSCLC: Emerging Therapies Shaping Future Sequencing
EGFR-Mutated NSCLC: Using Post-Progression Data to Guide 1L Strategies